Dexamethasone, Carmustine, Etoposide, Cytarabine, and Melphalan (Dexa-BEAM) Followed by High-Dose Chemotherapy and Stem Cell Rescue - A Highly Effective Regimen for Patients with Refractory or Relapsed Indolent Lymphoma

References

• Armitage JO. Treatment of non-Hodgkin's Lymphoma. New Engl J Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–83
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. New Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Young CY, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: Watchful waiting vs aggressive combined modality treatment. Sem Hematol 1988; 25: 11–16
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the groupe d'etude des lymphomes foliculaires. J Clin Oncol 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Johnson P WN, Rohatiner A ZS, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20 year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Bastion Y, Berger F, Bryon PA, et al. Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2(Suppl 2)123–129
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Anderson T, DeVita VT, Simon RM, et al. Malignant lymphoma. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–2721
   PubMed Web of Science ®Google Scholar
• Coiffier B, Bastion Y, Berger F, et al. Prognostic factors in follicular lymphomas. Semin Oncol 1993; 20: 89–95
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the international index for aggressive lymphomas to patients with low grade lymphoma. J Clin Oncol 1994; 12: 1343–1351
   PubMed Web of Science ®Google Scholar
• Spinolo JA, Cabanillas F, Dixon DO, et al. Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure. Ann Oncol 1992; 3: 227–232
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Bruce WB, Meeker BE, Valeriote FA, et al. Comparison of the sensitivity of normal haematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 1966; 36: 233–245
   PubMedGoogle Scholar
• Frei E, Canellos GP, Dose. A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Bishop MR, Bierman PJ, Vose JM, et al. The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4(Suppl 1)1–6
   PubMedGoogle Scholar
• Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262
   PubMed Web of Science ®Google Scholar
• Schouten HC, Colombat P, Verdonck LF, et al. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: The European Bone Marrow Transplantation Group experience. Ann Oncol 1994; 5(Suppl 2)147–149
   PubMedGoogle Scholar
• Rohatiner A ZS, Johnson P WM, Price C GA, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177–1184
   PubMed Web of Science ®Google Scholar
• Gupta RK, Lister TA. Current management of follicular lymphoma. Curr Opin Oncol 1996; 8: 360–365
   PubMedGoogle Scholar
• Lister TA. The management of follicular lymphoma. Ann Oncol 1991; 2(Suppl 2)131–135
   PubMed Web of Science ®Google Scholar
• Garvin AJ, Simon RM, Osborne CK, et al. An autopsy study of histologic progression in non-Hodgkin's lymphoma. 192 cases from the National Cancer Institute. Cancer 1983; 52: 393–401
   PubMed Web of Science ®Google Scholar
• Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579–2584
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457–481
   Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H. A Revised European-American Classification of Lymphoid Neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Haas R, Moos M, Karcher A, Möhle R, et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade Non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685–1692
   PubMed Web of Science ®Google Scholar
• Freedman AS, Ritz J, Neuberg D, et al. Autologous bone marrow transplantation in 69 patients with a history of low-grad B-cell Non-Hodgkin's lymphoma. Blood 1991; 77: 2524–2529
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993; 11: 704–711
   PubMed Web of Science ®Google Scholar
• Rappoport AP, Rowe JM, Kouides PA, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Josting A, Kátay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann of Oncol 1998; 9: 289–295
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• Colombat P, Binet C, Linassier C, et al. High dose chemotherapy with autologous marrow transplantation in follicular lymphoma. Leuk Lymph 1992; 7(Suppl)3–7
   PubMed Web of Science ®Google Scholar
• Signori O, Alexanian R. Waldenström's macroglobulinemia: A study of 50 patients. Proc Am Soc Clin Oncol 1981; 2: 523–528
   Google Scholar
• Kantarjian HM, Alexanian R, Koller CA, et al. Fludarabine therapy in magroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Skipper HE. Stepwise progress in the treatment of disseminated cancers. Cancer 1983; 51: 1773–1776
   PubMed Web of Science ®Google Scholar